Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma

ISSN： 1042-8194

Source： Leukemia and Lymphoma, Vol.54, Iss.7, 2013-07, pp. : 1473-1478

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The evolution and impact of therapy in multiple myeloma

By Laubach Jacob Richardson Paul Anderson Kenneth

Medical Oncology, Vol. 27, Iss. 1, 2010-06 ,pp. : 1-6

Humana Press, Inc

Access to resources Recommend Favorite

Bisphosphonate Anticancer Activity in Multiple Myeloma

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 12, Iss. 2, 2012-01 ,pp. : 123-128

Bentham Science Publishers

Access to resources Recommend Favorite

Angiogenic Activity of Mesenchymal Stem Cells in Multiple Myeloma

By Wang Xiaofang Zhang Zhiqing Yao Cheng

Cancer Investigation, Vol. 29, Iss. 1, 2011-01 ,pp. : 37-41

Informa Healthcare

Access to resources Recommend Favorite

Role of the microenvironment in multiple myeloma bone disease

By Huston Alissa Roodman G David

Future Oncology, Vol. 2, Iss. 3, 2006-06 ,pp. : 371-378

Future Medicine

Access to resources Recommend Favorite

Pain therapy in multiple myeloma — clinical experience from an observational study

By Lannert Heinrich

The Pain Clinic, Vol. 18, Iss. 2, 2006-04 ,pp. : 131-136

Maney Publishing

Access to resources Recommend Favorite